45 related articles for article (PubMed ID: 28676933)
1. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.
de Velasco G; Gray KP; Hamieh L; Urun Y; Carol HA; Fay AP; Signoretti S; Kwiatkowski DJ; McDermott DF; Freedman M; Pomerantz MM; Choueiri TK
Eur Urol Focus; 2016 Dec; 2(6):633-639. PubMed ID: 28723497
[TBL] [Abstract][Full Text] [Related]
3. The hidden dangers of short-term glucocorticoid use in children: A genomic analysis.
Xu X; Li Y; Han T; Zhao Y; Wang X; Fu X; Mao H
Int Immunopharmacol; 2024 Jun; 135():112323. PubMed ID: 38788448
[TBL] [Abstract][Full Text] [Related]
4. Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective.
Kivrane A; Ulanova V; Grinberga S; Sevostjanovs E; Viksna A; Ozere I; Bogdanova I; Zolovs M; Ranka R
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543282
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.
Maillard M; Chevreau C; Le Louedec F; Cassou M; Delmas C; Gourdain L; Blay JY; Cupissol D; Bompas E; Italiano A; Isambert N; Delcambre-Lair C; Penel N; Bertucci F; Guillemet C; Plenecassagnes J; Foulon S; Chatelut É; Le Cesne A; Thomas F
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291741
[TBL] [Abstract][Full Text] [Related]
6. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
7. Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer.
Delgado A; Enkemann S
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240915
[TBL] [Abstract][Full Text] [Related]
8. Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease.
Jiang Z; Wu Z; Liu R; Du Q; Fu X; Li M; Kuang Y; Lin S; Wu J; Xie W; Shi G; Peng Y; Zheng F
Front Pharmacol; 2023; 14():1102810. PubMed ID: 36923356
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.
Selim MS; Kassem AB; El-Bassiouny NA; Salahuddin A; Abu El-Ela RY; Hamza MS
Med Oncol; 2023 Jan; 40(2):80. PubMed ID: 36650399
[TBL] [Abstract][Full Text] [Related]
10. Genetic diversity of 'Very Important Pharmacogenes' in two South-Asian populations.
Bharti N; Banerjee R; Achalere A; Kasibhatla SM; Joshi R
PeerJ; 2021; 9():e12294. PubMed ID: 34824904
[TBL] [Abstract][Full Text] [Related]
11. Pregnane X Receptor (PXR) Polymorphisms and Cancer Treatment.
Skandalaki A; Sarantis P; Theocharis S
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439808
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
[TBL] [Abstract][Full Text] [Related]
13. miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5.
Wang L; Chen W; Zha J; Yan Y; Wei Y; Chen X; Zhu X; Ge L
Oncol Rep; 2019 Sep; 42(3):973-990. PubMed ID: 31322243
[TBL] [Abstract][Full Text] [Related]
14. Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data.
Giulietti M; Occhipinti G; Righetti A; Bracci M; Conti A; Ruzzo A; Cerigioni E; Cacciamani T; Principato G; Piva F
Front Oncol; 2018; 8():450. PubMed ID: 30370253
[TBL] [Abstract][Full Text] [Related]
15. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
Mbatchi LC; Gassiot M; Pourquier P; Goberna A; Mahammedi H; Mourey L; Joly F; Lumbroso S; Evrard A; Houede N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):653-659. PubMed ID: 28676933
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Habuchi T; Suzuki T
Steroids; 2008 Oct; 73(11):1052-9. PubMed ID: 18502461
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
